Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift in: Endocrine Connections Volume 10 Issue 1 (2021)
Cinacalcet Hydrochloride API Manufacturer | CAS 364782-34-3 API Supplier - Dr. Reddy's
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and Design Overview | American Society of Nephrology
Cinacalcet: Dosage, Mechanism/Onset of Action, Half-Life - Medicine.com
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis | NEJM
Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism - ScienceDirect
Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease - Kidney International
A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro
Frontiers | Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism | Endocrinology
Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease - Kidney International
PDF) Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis | NEJM
Pharmacological and clinical properties of calcimimetics: Calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism - ScienceDirect
Cinacalcet | C22H22F3N - PubChem
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis | NEJM
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis | NEJM
Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism - Akizawa - 2020 - Therapeutic Apheresis and Dialysis - Wiley Online Library
Direct bone effects of calcimimetics in chronic kidney disease? - Kidney International
Frontiers | Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism | Endocrinology
Cinacalcet - an overview | ScienceDirect Topics
Cinacalcet | C22H22F3N - PubChem
Cinacalcet: will it play a role in reducing cardiovascular events? | Future Cardiology
American Association of Endocrine Surgeons on Twitter: "Cinacalcet doesn't impact the bone mineral density in patients w/ primary hyperparathyroidism & is only FDA approved for severe hypercalcemia in patients who are unable
Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease - Kidney International
